Brett Lewis, general manager of Roche Diabetes Care UK and Ireland, said: "I’m delighted to be embarking on this important research programme with Ieso, whose pioneering cognitive and ...

Roche Diabetes Care’s Michael Goetzl explains how the company is spearheading a combined digital-pharmaceutical approach to diabetes and how pharma firms can best embrace holistic strategies.

Our Future,” specifically highlights the economic power of care, and for diabetes solutions companies like Roche Diabetes Care (RDC), the contribution nurses make to patients is undeniable ...

Baylor Medicine is proud to offer patients a team of physicians that collaborate on the treatment of diabetes and how to continue to improve care for their patients. We work together with our patients ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A multi-institutional group of researchers led by the Hubrecht Institute and Roche's Institute of Human Biology has developed strategies to identify regulators of intestinal hormone secretion.

getting an accurate and timely diagnosis is critical to providing the best care for patients and curbing transmission,” said Matt Sause, CEO of Roche Diagnostics. “Using TAGS technology ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Brian Roche co-anchors News 8 at 5 p.m. each weekday. He is also the 8 On Your Side Consumer/Investigative reporter for News 8. Brian is an Emmy Award winning anchor and reporter. He has been ...

MANNHEIM, Germany, Oct 9 (Reuters) - Roche's (ROG.S), opens new tab experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion ...

Roche (RHHBY) announced that a detailed analysis of the positive phase III INAVO120 results, evaluating Itovebi in combination with palbociclib and fulvestrant were published in the New England ...